Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAB Atlantic Coastal Acquisition Corp. II	$5.77 -47.1%	$8.44	$5.75 ▼ $13.00	$47.14M	0.01	9,443 shs	162,400 shs
KOD Kodiak Sciences	$3.45 -3.4%	$3.32	$1.92 ▼ $11.60	$182.04M	2.42	344,373 shs	590,286 shs
NBTX Nanobiotix	$4.11 -0.6%	$3.49	$2.76 ▼ $7.29	$193.53M	0.26	15,556 shs	6,644 shs
URGN UroGen Pharma	$4.04 +1.8%	$9.25	$3.42 ▼ $20.70	$195.49M	0.66	703,678 shs	2.90 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAB Atlantic Coastal Acquisition Corp. II	0.00%	0.00%	0.00%	0.00%	-47.74%
KOD Kodiak Sciences	0.00%	+0.29%	-28.13%	-11.54%	+8.49%
NBTX Nanobiotix	0.00%	+8.08%	+19.19%	+15.01%	-41.68%
URGN UroGen Pharma	0.00%	-3.58%	-64.90%	-56.42%	-69.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAB Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	4.1477 of 5 stars	3.0	3.0	0.0	4.6	2.0	3.3	0.6
NBTX Nanobiotix	1.5093 of 5 stars	3.3	2.0	0.0	0.0	2.1	0.0	0.6
URGN UroGen Pharma	4.0683 of 5 stars	4.4	1.0	0.0	4.5	2.2	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAB Atlantic Coastal Acquisition Corp. II	0.00	N/A	N/A	N/A
KOD Kodiak Sciences	2.00	Hold	$9.00	160.87% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	94.84% Upside
URGN UroGen Pharma	2.88	Moderate Buy	$27.43	578.93% Upside

Current Analyst Ratings Breakdown

Latest ACAB, KOD, NBTX, and URGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	URGN UroGen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $15.00
5/22/2025	URGN UroGen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $3.00
5/22/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/13/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/8/2025	URGN UroGen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
4/29/2025	URGN UroGen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/28/2025	URGN UroGen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
4/28/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
4/17/2025	URGN UroGen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$22.00 ➝ $16.00
4/16/2025	URGN UroGen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$23.00
4/4/2025	NBTX Nanobiotix	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $8.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAB Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$5.07 per share	N/A
NBTX Nanobiotix	-$11.61M	-16.67	N/A	N/A	($0.04) per share	-102.65
URGN UroGen Pharma	$91.87M	2.03	N/A	N/A	($2.78) per share	-1.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAB Atlantic Coastal Acquisition Corp. II	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	-$260.49M	-$3.63	N/A	N/A	N/A	N/A	-84.52%	-45.40%	8/13/2025 (Estimated)
NBTX Nanobiotix	-$42.97M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
URGN UroGen Pharma	-$102.24M	-$3.18	N/A	N/A	N/A	-129.11%	N/A	-47.94%	8/12/2025 (Estimated)

Latest ACAB, KOD, NBTX, and URGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/12/2025	Q1 2025	URGN UroGen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million
3/27/2025	Q4 2024	KOD Kodiak Sciences	-$0.90	-$0.84	+$0.06	-$0.84	N/A	N/A
3/10/2025	Q4 2024	URGN UroGen Pharma	-$0.69	-$0.80	-$0.11	-$0.80	$25.25 million	$24.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAB Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
URGN UroGen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAB Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	8.42	8.42
NBTX Nanobiotix	N/A	1.42	N/A
URGN UroGen Pharma	4.77	9.00	8.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAB Atlantic Coastal Acquisition Corp. II	23.30%
KOD Kodiak Sciences	89.06%
NBTX Nanobiotix	38.81%
URGN UroGen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
ACAB Atlantic Coastal Acquisition Corp. II	91.19%
KOD Kodiak Sciences	45.30%
NBTX Nanobiotix	3.45%
URGN UroGen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAB Atlantic Coastal Acquisition Corp. II	4	8.17 million	720,000	Not Optionable
KOD Kodiak Sciences	90	52.76 million	28.79 million	Optionable
NBTX Nanobiotix	100	47.13 million	45.51 million	Not Optionable
URGN UroGen Pharma	200	46.11 million	22.26 million	Optionable

ACAB, KOD, NBTX, and URGN Headlines

Recent News About These Companies

URGN LAWSUIT ALERT: Levi & Korsinsky Notifies UroGen Pharma Ltd. Investors - Lead Plaintiff Deadline July 28, 2025

June 2 at 7:30 AM | accessnewswire.com

URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

June 2 at 7:00 AM | accessnewswire.com

UroGen Pharma Ltd. (NASDAQ:URGN) Receives $27.43 Consensus Price Target from Brokerages

June 2 at 2:09 AM | americanbankingnews.com

URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN)

June 1 at 5:57 PM | businesswire.com

URGN FRAUD ALERT: UroGen Pharma Ltd. Investors are Alerted to Contact BFA Law about the Pending Securities Fraud Class Action

June 1 at 5:57 PM | stockhouse.com

Lost Money on UroGen Pharma Ltd. (URGN)? Join Class Action Before July 28, 2025 - Contact Levi & Korsinsky

June 1 at 5:07 PM | accessnewswire.com

Recover Investment Losses: Levi & Korsinsky Files Class Action Against UroGen Pharma Ltd. (URGN)

June 1 at 10:15 AM | accessnewswire.com

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

June 1 at 10:00 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 1 at 10:00 AM | prnewswire.com

July 28, 2025 Deadline Approaching: Join Class Action Against UroGen Pharma Ltd. (URGN) - Contact Levi & Korsinsky

June 1 at 9:45 AM | accessnewswire.com

Securities Lawsuit Alert: UroGen Pharma Ltd. (URGN) Investors - Contact Levi & Korsinsky Before July 28, 2025

June 1 at 7:32 AM | accessnewswire.com

URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

June 1 at 7:00 AM | accessnewswire.com

URGN ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against UroGen Pharma Ltd. July 28, 2025 Deadline

June 1 at 6:30 AM | accessnewswire.com

URGN CLASS ACTION NOTICE: UroGen Pharma Ltd. ...

May 31 at 7:12 PM | gurufocus.com

URGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. ...

May 31 at 7:12 PM | gurufocus.com

Class Action Lawsuit Filed: UroGen Pharma Ltd. (URGN) - Join by July 28, 2025 - Contact Levi & Korsinsky

May 31 at 6:01 PM | accessnewswire.com

URGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 31 at 9:40 AM | businesswire.com

URGN CLASS ACTION NOTICE: UroGen Pharma Ltd. has been Sued for Securities Fraud after Stock Plummets 45% – Contact BFA Law if You Suffered Losses (NASDAQ:URGN)

May 31 at 7:07 AM | globenewswire.com

Deadline Alert: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

May 31 at 1:21 AM | tmcnet.com

UroGen Pharma Ltd. (NASDAQ:URGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

May 31 at 1:09 AM | marketbeat.com

URGN FRAUD NOTICE: A Class Action Was Filed on Behalf of UroGen Pharma Ltd. Shareholders for Securities Fraud - Contact BFA Law by July 28 Court Deadline

May 30 at 7:46 PM | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAB, KOD, NBTX, and URGN Company Descriptions

Atlantic Coastal Acquisition Corp. II NASDAQ:ACAB

Atlantic Coastal Acquisition Corp. II does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in financial services industry and mobility sector. The company was incorporated in 2021 and is based in New York, New York. Atlantic Coastal Acquisition Corp. II is a subsidiary of Atlantic Coastal Acquisition Management II LLC.

Kodiak Sciences NASDAQ:KOD

$3.45 -0.12 (-3.36%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.70 +0.25 (+7.10%)

As of 08:19 AM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Nanobiotix NASDAQ:NBTX

$4.11 -0.02 (-0.58%)

Closing price 05/30/2025 03:45 PM Eastern

Extended Trading

$4.10 -0.01 (-0.15%)

As of 07:48 AM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

UroGen Pharma NASDAQ:URGN

$4.04 +0.07 (+1.76%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$4.40 +0.36 (+8.91%)

As of 08:42 AM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time